No connection

Search Results

EOLS vs MASS

EOLS
Evolus, Inc.
NEUTRAL
Price
$4.09
Market Cap
$266.1M
Sector
Healthcare
AI Confidence
80%
MASS
908 Devices Inc.
BEARISH
Price
$7.20
Market Cap
$269.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
EOLS
--
MASS
--
Forward P/E
EOLS
17.04
MASS
-24.41
P/B Ratio
EOLS
-11.52
MASS
1.82
P/S Ratio
EOLS
0.9
MASS
4.79
EV/EBITDA
EOLS
-12.2
MASS
-7.75

Profitability

Gross Margin
EOLS
66.33%
MASS
51.11%
Operating Margin
EOLS
-0.32%
MASS
-17.3%
Profit Margin
EOLS
-17.38%
MASS
34.68%
ROE
EOLS
--
MASS
-25.77%
ROA
EOLS
-10.25%
MASS
-9.02%

Growth

Revenue Growth
EOLS
14.4%
MASS
-7.7%
Earnings Growth
EOLS
--
MASS
--

Financial Health

Debt/Equity
EOLS
--
MASS
0.03
Current Ratio
EOLS
1.9
MASS
4.24
Quick Ratio
EOLS
1.44
MASS
3.65

Dividends

Dividend Yield
EOLS
--
MASS
--
Payout Ratio
EOLS
0.0%
MASS
0.0%

AI Verdict

EOLS NEUTRAL

EOLS shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.

Strengths
Company has established market presence
Risks
Low profit margin of -17.4%
MASS BEARISH

The company exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating a critical lack of fundamental strength. While the balance sheet shows strong liquidity (Current Ratio 4.24) and minimal debt (Debt/Equity 0.03), these are offset by negative revenue growth (-7.70% YoY) and persistent operating losses. Insider sentiment is strongly bearish, with the CEO, CFO, and Directors selling shares amidst a long-term price collapse of 85.9% over five years. The disconnect between the high reported profit margin and the negative operating margin suggests non-operational gains rather than a sustainable business model.

Strengths
Strong short-term liquidity with a Current Ratio of 4.24
Very low leverage with a Debt/Equity ratio of 0.03
Healthy Gross Margins at 51.11%
Risks
Critical financial health failure as indicated by Piotroski F-Score (1/9)
Negative organic growth with YoY revenue declining by 7.70%
Negative operating margins (-17.30%) indicating an unsustainable cost structure

Compare Another Pair

EOLS vs MASS: Head-to-Head Comparison

This page compares Evolus, Inc. (EOLS) and 908 Devices Inc. (MASS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile